Roivant Sciences reported a quiet Q1 2026 but highlighted progress across its inflammation and immunology pipeline, alongside a US$950 million settlement received from Moderna related to lipid ...
Source LinkRoivant Sciences reported a quiet Q1 2026 but highlighted progress across its inflammation and immunology pipeline, alongside a US$950 million settlement received from Moderna related to lipid ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.